JP2024508808A5 - - Google Patents
Info
- Publication number
- JP2024508808A5 JP2024508808A5 JP2023551180A JP2023551180A JP2024508808A5 JP 2024508808 A5 JP2024508808 A5 JP 2024508808A5 JP 2023551180 A JP2023551180 A JP 2023551180A JP 2023551180 A JP2023551180 A JP 2023551180A JP 2024508808 A5 JP2024508808 A5 JP 2024508808A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- car
- cancer
- sequence
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163154618P | 2021-02-26 | 2021-02-26 | |
| US63/154,618 | 2021-02-26 | ||
| PCT/US2022/018117 WO2022183101A1 (en) | 2021-02-26 | 2022-02-28 | Anti-muc1-c antibodies and car-t structures |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024508808A JP2024508808A (ja) | 2024-02-28 |
| JP2024508808A5 true JP2024508808A5 (enExample) | 2025-03-07 |
Family
ID=80780549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023551180A Pending JP2024508808A (ja) | 2021-02-26 | 2022-02-28 | 抗ｍｕｃ１－ｃ抗体及びｃａｒ－ｔ構造 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240182597A1 (enExample) |
| EP (1) | EP4298129A1 (enExample) |
| JP (1) | JP2024508808A (enExample) |
| KR (1) | KR20230150825A (enExample) |
| CN (1) | CN116917327A (enExample) |
| AU (1) | AU2022226565A1 (enExample) |
| CA (1) | CA3211142A1 (enExample) |
| MX (1) | MX2023009882A (enExample) |
| WO (1) | WO2022183101A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL322083A (en) | 2016-08-24 | 2025-09-01 | Teneobio Inc | Non-human transgenic animals that produce modified heavy chain antibodies only |
| IL317134A (en) | 2016-12-21 | 2025-01-01 | Teneobio Inc | An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation |
| CN111683966B (zh) | 2017-12-22 | 2023-07-11 | 特尼奥生物股份有限公司 | 与cd22结合的重链抗体 |
| WO2020206330A1 (en) | 2019-04-05 | 2020-10-08 | Teneobio, Inc. | Heavy chain antibodies binding to psma |
| CR20210622A (es) | 2019-06-14 | 2022-06-27 | Teneobio Inc | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 |
| WO2025218621A1 (zh) * | 2024-04-15 | 2025-10-23 | 原启生物科技(上海)有限责任公司 | 靶向muc1的抗原结合蛋白 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| WO2004042017A2 (en) | 2002-10-31 | 2004-05-21 | Genentech, Inc. | Methods and compositions for increasing antibody production |
| EP1585768A2 (en) | 2003-01-23 | 2005-10-19 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| KR101151957B1 (ko) | 2004-07-22 | 2012-06-01 | 로저 킹돈 크레이그 | 결합 분자 |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| MX341884B (es) | 2009-03-10 | 2016-09-07 | Biogen Ma Inc | Anticuerpos anti-antigeno de maduracion de celulas b (bcma). |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| WO2015116753A1 (en) * | 2014-01-29 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Antibodies against the muc1-c/extracellular domain (muc1-c/ecd) |
| KR20250175345A (ko) | 2016-06-21 | 2025-12-16 | 테네오바이오, 인코포레이티드 | Cd3 결합 항체 |
| WO2018014039A1 (en) * | 2016-07-15 | 2018-01-18 | Poseida Therapeutics, Inc. | Chimeric antigen receptors (cars) specific for muc1 and methods for their use |
| IL322083A (en) | 2016-08-24 | 2025-09-01 | Teneobio Inc | Non-human transgenic animals that produce modified heavy chain antibodies only |
| PE20241349A1 (es) | 2016-09-14 | 2024-07-03 | Teneobio Inc | Anticuerpos de union a cd3 |
| AU2020407235A1 (en) * | 2019-12-20 | 2022-07-07 | Poseida Therapeutics, Inc. | Anti-MUC1 compositions and methods of use |
-
2022
- 2022-02-28 US US18/547,663 patent/US20240182597A1/en active Pending
- 2022-02-28 WO PCT/US2022/018117 patent/WO2022183101A1/en not_active Ceased
- 2022-02-28 KR KR1020237031883A patent/KR20230150825A/ko active Pending
- 2022-02-28 EP EP22710882.6A patent/EP4298129A1/en active Pending
- 2022-02-28 AU AU2022226565A patent/AU2022226565A1/en active Pending
- 2022-02-28 CN CN202280016735.6A patent/CN116917327A/zh active Pending
- 2022-02-28 JP JP2023551180A patent/JP2024508808A/ja active Pending
- 2022-02-28 CA CA3211142A patent/CA3211142A1/en active Pending
- 2022-02-28 MX MX2023009882A patent/MX2023009882A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024508808A5 (enExample) | ||
| JP7562528B2 (ja) | 抗体及びその用途 | |
| JP7685095B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| TWI821474B (zh) | Ｃｄ３抗體及其藥物用途 | |
| CN103687879B (zh) | 多价抗原结合fv分子 | |
| JP2024507540A5 (enExample) | ||
| JP7399852B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| JP2018502050A5 (enExample) | ||
| JP2021530236A5 (enExample) | ||
| CN113330034A (zh) | 针对B7-H3的IgV结构域的单克隆抗体及其用途 | |
| JP2022505445A5 (enExample) | ||
| JP2022550243A (ja) | 抗ｐｄ－１抗体及びその使用 | |
| JP2020502233A5 (enExample) | ||
| KR20210107747A (ko) | 항체 융합 단백질, 이의 제조 방법 및 이의 적용 | |
| JP2026510999A (ja) | Ｃｄ１９／ｃｄ３８多重特異性抗体 | |
| WO2022194201A1 (zh) | 一种靶向cldn18.2的抗体或其抗原结合片段及其应用 | |
| KR20250028265A (ko) | 항체 및 이의 용도 | |
| KR20250012612A (ko) | 고형 종양을 치료하는 방법 | |
| CN116496398B (zh) | 一种特异性结合CD44的v5外显子的抗体及其用途 | |
| TWI922434B (zh) | 一種融合蛋白及其用途 | |
| WO2025167974A1 (zh) | 多特异性抗体或抗原结合片段 | |
| HK40111322A (zh) | 多特异性抗体及其制备和使用方法 | |
| HK40111323A (zh) | 多特异性抗体及其制备和使用方法 | |
| TW202400232A (zh) | 多特異性分子與免疫檢查點抑制劑之組合 | |
| KR20250021381A (ko) | 인테그린 베타-2를 표적화하는 항체 |